DurVena


Developer of a photochemical tissue passivation therapy for reinforcing harvested vein grafts prior to arterial implantation. The technology uses a topically applied photosensitizer activated by light to increase collagen crosslinking in the vein adventitia, with published preclinical data reporting increased vein stiffness and reduced intimal hyperplasia. The program has been advanced through preclinical GLP testing, is covered by an international patent portfolio, and has received FDA Breakthrough Device designation.

Industries

health-care
health-diagnostics
medical

Nr. of Employees

small (1-50)

DurVena

Mission, Kansas, United States, North America


Products

Photochemical tissue passivation system for vein graft preparation

A surgical system that applies a photosensitizer to harvested veins and uses light activation to create adventitial collagen crosslinks prior to arterial implantation, intended to increase graft stiffness and reduce intimal hyperplasia.


Services

Clinical training and onboarding support

Training and support for surgical teams to implement the tissue passivation protocol and to participate in upcoming clinical trials.

Expertise Areas

  • Vascular graft reinforcement
  • Preclinical GLP study design and execution (small and large animal models)
  • Photosensitizer-activated tissue modification
  • Medical device regulatory strategy (Breakthrough Device pathway)
  • Show More (2)

Key Technologies

  • Photochemical tissue passivation
  • Photosensitizer-mediated collagen crosslinking
  • LED-based light activation
  • GLP animal models
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.